Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Explore the Next Generation Manufacturing of the Most Potent Compounds in Pharma | Contract Pharma

What are you searching for?

Sign in
Sponsored Content

Explore the Next Generation Manufacturing of the Most Potent Compounds in Pharma

MilliporeSigma's new HPAPI contract manufacturing facility brings unmatched capacity to the market.

Released By MilliporeSigma

HPAPIs are a rapidly expanding group of therapeutics due to the recent commercial approvals of 8 ADCs and other targeted therapies. In recent years, the pharmaceutical industry has been moving towards drugs with increasing potency, including ones with OELs in the single nanograms/m3. This shift is occurring as a result of better targeted therapies in the oncology space as well as due to more toxicological data about previously approved APIs.  With much of this work being outsourced, many contract manufacturing organizations wishing to operate in this field have had to update their processes to handle these materials and ensure the safety of their operators.  In this presentation we will show how MilliporeSigma has met these challenges and ready to lead in this area moving forward.

Join our webinar to learn more about the evolution of the high potent API manufacturing industry from 10 µg to single nanogram limits, explore different safety concepts to handle highly potent compounds and expand your knowledge about the most commonly used payload classes in the ADC field.

Register Now!



Request more information from MilliporeSigma

Request more information from MilliporeSigma

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics